Unicycive Therapeutics (UNCY)
(Delayed Data from NSDQ)
$0.46 USD
+0.02 (3.86%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $0.46 0.00 (0.66%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
UNCY 0.46 +0.02(3.86%)
Will UNCY be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for UNCY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for UNCY
Unicycive (UNCY) Up on Positive Hyperphosphatemia Study Update
UNCY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for UNCY
Unicycive Therapeutics management to meet virtually with Piper Sandler
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Unicycive Therapeutics Granted Patent on UNI-494 to Treat Acute Kidney Injury by the United States Patent and Trademark Office (USPTO)
Unicycive Therapeutics granted patent on UNI-494 from USPTO
Unicycive Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 3rd Annual Kidney Virtual Conference